Bioresorbable Drug-Eluting Stents

Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.

BACKGROUND The performance of everolimus-eluting bioresorbable vascular scaffold (BVS) versus drug-eluting metallic stent (DES) in the same individual receiving multilesion percutaneous coronary intervention (PCI) remains poorly studied. This report investigates the intraindividual performance of BVS and DES in patients receiving multilesion PCI and follow-up angiography. METHODS AND RESULTS ...

Drug-eluting stents.

New Drug-Eluting Stents

The introduction of drug-eluting stents (DES) has rapidly and profoundly affected the field of interventional cardiology, and DESs are now used in a majority of intracoronary stenting procedures. As a result of the innumerable “trial-and-error” endeavors, DESs have emerged as a potential solution for solving the problem of restenosis. DESs are coated stents capable of releasing single or multip...

Drug-Eluting Stents

n the history of percutaneous coronary intervention, drug-eluting stents (DES) are recognized as revolutionary technologies with their unique ability to provide both mechanical and biological solutions simultaneously to the target lesion. While the clinical success of DES depends on these 2 properties, the ability of the operator to properly deploy the device is also of utmost importance. Altho...

Drug-eluting/biodegradable stents.